Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Alnylam Pharmaceuticals Inc Stock Research

ALNY

173.85USD-1.67(-0.95%)Market Closed
Watchlist

Market Summary

USD173.85-1.67
Market Closed
-0.95%

ALNY Alerts

  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

ALNY Stock Price

ALNY RSI Chart

ALNY Valuation

Market Cap

21.9B

Price/Earnings (Trailing)

-20.61

Price/Sales (Trailing)

17.72

EV/EBITDA

-24.24

Price/Free Cashflow

-40.55

ALNY Price/Sales (Trailing)

ALNY Profitability

EBT Margin

-92.70%

Return on Equity

714.91%

Return on Assets

-31.4%

Free Cashflow Yield

-2.47%

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

41.78%

Revenue Q/Q

-0.17%

ALNY Earnings

Earnings (TTM)

-1.1B

Earnings Y/Y

0.5%

Earnings Q/Q

-58.54%

Price Action

52 Week Range

171.08242.97
(Low)(High)

Last 7 days

-17%

Last 30 days

-7.0%

Last 90 days

-11.8%

Trailing 12 Months

-17.2%

ALNY Financial Health

Current Ratio

3.77

ALNY Investor Care

Shares Dilution (1Y)

3.31%

Diluted EPS (TTM)

-8.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ALNY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-07
Garg Pushkal
sold
-766,083
183
-4,166
cmo & evp dev & med affairs
2023-08-04
Vaishnaw Akshay
sold
-753,986
185
-4,057
president
2023-08-04
Greenstreet Yvonne
sold
-753,986
185
-4,057
chief executive officer
2023-08-04
Poulton Jeffrey V.
sold
-643,037
185
-3,460
evp, chief financial officer
2023-08-04
Garg Pushkal
sold
-643,223
185
-3,461
cmo & evp dev & med affairs
2023-08-03
Poulton Jeffrey V.
acquired
-
-
7,627
evp, chief financial officer
2023-08-03
Vaishnaw Akshay
acquired
-
-
8,941
president
2023-08-03
BONNEY MICHAEL W
sold
-1,195,310
185
-6,448
-
2023-08-03
Greenstreet Yvonne
acquired
-
-
8,941
chief executive officer
2023-08-03
Garg Pushkal
acquired
-
-
7,627
cmo & evp dev & med affairs

1–10 of 50

Which funds bought or sold ALNY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
31.25
784
3,989
-%
2023-08-29
EFG Asset Management (Americas) Corp.
added
3.66
-51,951
2,988,710
0.69%
2023-08-28
DT Investment Partners, LLC
unchanged
-
-64.00
946
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-30,102
550,826
-%
2023-08-21
BOKF, NA
reduced
-2.88
-81,914
952,739
0.02%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.29
-2,995,740
37,721,700
0.05%
2023-08-21
OSAIC HOLDINGS, INC.
added
7.57
17,343
771,759
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-16.59
-2,617,000
9,894,000
0.10%
2023-08-18
Humankind Investments LLC
new
-
211,403
211,403
0.08%
2023-08-17
Orion Portfolio Solutions, LLC
reduced
-5.15
-50,096
447,499
-%

1–10 of 43

Latest Funds Activity

Are funds buying ALNY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALNY
No. of Funds

Schedule 13G FIlings of Alnylam Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
3.3%
4,074,144
SC 13G/A
Feb 13, 2023
capital world investors
13.5%
16,593,958
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.35%
11,507,116
SC 13G/A
Feb 06, 2023
wellington management group llp
5.09%
6,261,642
SC 13G/A
Jan 31, 2023
blackrock inc.
7.0%
8,665,702
SC 13G/A
Jan 19, 2023
baillie gifford & co
7.65%
9,407,871
SC 13G/A
Sep 09, 2022
capital world investors
10.7%
12,816,777
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.4%
6,535,368
SC 13G
Feb 09, 2022
vanguard group inc
8.95%
10,702,771
SC 13G/A

Recent SEC filings of Alnylam Pharmaceuticals

View All Filings
Date Filed Form Type Document
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
144
Notice of Insider Sale Intent
Aug 04, 2023
4
Insider Trading
Aug 03, 2023
8-K
Current Report
Aug 03, 2023
10-Q
Quarterly Report
Jul 26, 2023
8-K
Current Report
Jun 30, 2023
8-K
Current Report

Peers (Alternatives to Alnylam Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.4B
56.0B
2.30% 9.45%
31.25
4.84
-2.31% -31.27%
265.4B
1.8B
-1.67% 25.43%
-153.19
146.56
69.45% 14.65%
90.8B
9.5B
0.45% 22.78%
26.99
9.56
13.83% 5.33%
89.0B
12.7B
-1.51% 18.09%
20.7
7.02
-10.94% -24.40%
21.9B
1.2B
-7.00% -17.21%
-20.61
17.72
39.94% -8.44%
11.0B
1.0B
3.70% 3.57%
-12.12
10.97
20.15% -79.16%
10.5B
2.1B
-3.12% 8.08%
12.05
4.98
18.01% 38.16%
MID-CAP
3.1B
225.6M
0.04% -28.00%
-5.53
13.59
-2.11% 21.02%
3.0B
-
-10.01% 147.80%
-9.03
-
- -28.88%
2.6B
402.9M
-2.14% -20.15%
-3.59
6.42
20.50% -42.46%
1.9B
27.2M
-14.18% -57.07%
-2.57
69.63
- -14.43%
SMALL-CAP
3.1B
-
-2.94% -39.70%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-16.58% -4.84%
11.18
4.26
77.72% 112.02%
281.2M
152.5M
-11.67% 38.41%
37.75
1.84
127.84% 103.41%
28.7M
-
1.35% 3552.08%
-0.62
-
- -31.51%

Alnylam Pharmaceuticals News

MarketBeat
ProShare Advisors LLC Sells 3227 Shares of Alnylam ....
MarketBeat,
15 hours ago
Yahoo Entertainment
13 Best Beaten Down Stocks To Buy Now.
Yahoo Entertainment,
31 hours ago
Best Stocks
finanznachrichten.de

Returns for ALNY

Cumulative Returns on ALNY

11.9%


10-Year Cumulative Returns

12.3%


7-Year Cumulative Returns

13.2%


5-Year Cumulative Returns

9.9%


3-Year Cumulative Returns

Risks for ALNY

What is the probability of a big loss on ALNY?

100%


Probability that Alnylam Pharmaceuticals stock will be more than 20% underwater in next one year

36.9%


Probability that Alnylam Pharmaceuticals stock will be more than 30% underwater in next one year.

17.7%


Probability that Alnylam Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ALNY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Alnylam Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Alnylam Pharmaceuticals

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue8.2%1,237,385,0001,143,449,0001,037,418,000960,918,000884,245,000879,980,000844,287,000749,314,000687,534,000570,943,000492,853,000400,972,000345,180,000285,932,000219,750,000169,102,000153,655,467138,208,933122,762,400107,315,86791,869,333
Operating Expenses---------------------719,688,000
  S&GA Expenses5.6%844,551,000799,846,000770,658,000746,696,000652,912,000628,251,000620,639,000600,548,000625,945,000608,518,000588,420,000578,406,000531,285,000516,158,000479,005,000431,416,000427,610,000399,520,000382,359,000341,126,000272,225,000
  R&D Expenses4.5%986,505,000943,691,000883,015,000850,026,000799,227,000776,150,000792,156,000731,575,000698,786,000671,147,000654,819,000687,651,000686,664,000695,558,000655,114,000584,849,000563,998,000537,690,000505,420,000492,156,000447,463,000
EBITDA100.0%--868,365,000-926,557,000-975,871,000-773,788,000-694,931,000-661,556,000-654,141,000-717,113,000-716,458,000-736,332,000-802,777,000-792,519,000-873,101,000-868,078,000------
EBITDA Margin100.0%--0.76-0.89-1.02-0.88-0.79-0.78-0.87-1.04-1.25-1.49-2.00-2.30-3.05-3.95------
Interest Expenses-8.8%129,987,000142,561,000155,968,000162,871,000162,061,000152,868,000143,021,000134,722,000123,179,000117,011,00084,496,00055,979,00027,248,000--------
Earnings Before Taxes0.0%-1,059,535,000-1,059,999,000-1,126,993,000-1,180,274,000-978,567,000-892,225,000-852,144,000-835,441,000-883,657,000-873,229,000-855,600,000-888,584,000-845,061,000-885,679,000-885,253,000-819,750,000-855,658,000-800,618,000-760,674,000-691,821,000-569,921,000
EBT Margin100.0%--0.93-1.09-1.23-1.11-1.01-1.01-1.11-1.29-1.53-1.74-2.22-2.45-3.10-4.03------
Net Income0.1%-1,063,538,000-1,064,916,000-1,131,156,000-1,182,123,000-980,717,000-892,874,000-852,824,000-837,904,000-886,681,000-876,351,000-858,281,000-890,926,000-846,170,000-886,422,000-886,116,000-821,372,000-858,119,000-802,198,000-761,497,000-692,283,000-569,938,000
Net Income Margin100.0%--0.93-1.09-1.23-1.11-1.01-1.01-1.12-1.29-1.53-1.74-2.22-2.45-3.10-4.03------
Free Cashflow100.0%--604,647,000-613,333,000-631,747,000-660,051,000-654,279,000-718,065,000-690,850,000-653,496,000-672,382,000-685,322,000-775,295,000-871,241,000-451,802,000-418,583,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.3%3,4023,3923,5463,5353,3303,4343,6433,4723,5093,2553,4073,3073,3742,2802,3952,5422,7162,0141,5751,6761,789
  Current Assets-0.7%2,5242,5412,6922,6912,4722,5902,8092,6752,7252,4702,6152,5552,1601,5851,7161,8972,0641,3921,2011,3421,503
    Cash Equivalents-2.1%6586728661,0735765348221,0947463804974975814685479231,136725420317361
  Inventory-23.8%10013212911589.0079.0086.0098.0084.0074.0075.0067.0077.0068.0056.0055.0041.0032.0024.0011.00-
  Net PPE0.8%527523523515508504502485471465465445439430425396372342321273228
Liabilities4.4%3,8113,6513,7053,6033,1543,0323,0552,7162,6562,3292,3912,0921,975930956935959467273198169
  Current Liabilities17.1%789673768773658606696611555495585480384339353353329149179122114
  Long Term Debt-----678677676434433192191----------
Shareholder's Equity-57.4%-408-259-158-1764015887568539261,0161,2151,4001,3501,4391,6071,7571,5471,3021,4781,621
  Retained Earnings-4.1%-7,019-6,743-6,569-6,361-5,955-5,678-5,438-5,179-4,975-4,785-4,585-4,341-4,088-3,909-3,727-3,450-3,242-3,022-2,840-2,629-2,384
  Additional Paid-In Capital1.9%6,6476,5226,4556,3376,1736,1176,0585,9695,8635,7475,6445,5935,5205,2905,2015,0915,0344,6024,1754,1404,038
Shares Outstanding0.5%125124124123121120120119118117116116115113112109109105101101101
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations11.9%-472-536-541-559-578-577-641-614-590-604-614-687-760-336-278-232-204-595-562-515-459
  Share Based Compensation18.8%28724123123213813916615515916114017218117717513717917015815795.00
Cashflow From Investing-63.0%89.00241169-104-506-492-27342.00120-477-435-558-558-406-41752.00158510273-136-369
Cashflow From Financing5.3%4604374266559311,2311,2471,17363399299581776348682378882241565.00767783

ALNY Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Total revenues$ 318,754$ 224,818$ 638,044$ 438,077
Operating costs and expenses:    
Cost of goods sold75,33634,038116,76857,495
Cost of collaborations and royalties10,0346,77023,47118,940
Research and development248,526205,712479,095375,605
Selling, general and administrative214,689169,984398,348324,455
Total operating costs and expenses548,585416,5041,017,682776,495
Loss from operations(229,831)(191,686)(379,638)(338,418)
Other (expense) income:    
Interest expense(30,035)(42,609)(58,990)(84,971)
Interest income21,0751,89939,7302,911
Other expense, net(35,418)(42,277)(47,673)(93,551)
Total other expense, net(44,378)(82,987)(66,933)(175,611)
Loss before income taxes(274,209)(274,673)(446,571)(514,029)
Provision for income taxes(1,815)(2,729)(3,554)(3,714)
Net loss$ (276,024)$ (277,402)$ (450,125)$ (517,743)
Net loss per common share - basic (in dollars per share)$ (2.21)$ (2.29)$ (3.62)$ (4.29)
Net loss per common share - diluted (in dollars per share)$ (2.21)$ (2.29)$ (3.62)$ (4.29)
Weighted-average common shares used to compute basic net loss per common share (in shares)124,659120,896124,387120,646
Weighted-average common shares used to compute diluted net loss per common share (in shares)124,659120,896124,387120,646
Statements of Comprehensive Loss    
Net loss$ (276,024)$ (277,402)$ (450,125)$ (517,743)
Other comprehensive income (loss):    
Unrealized (loss) gain on marketable securities(2,025)(1,734)2,100(8,951)
Foreign currency translation gain (loss)4,073(2,459)5,483(83)
Defined benefit pension plans, net of tax(4)34(9)69
Total other comprehensive income (loss)2,044(4,159)7,574(8,965)
Comprehensive loss(273,980)(281,561)(442,551)(526,708)
Net product revenues    
Revenues:    
Total revenues305,705213,515582,033400,387
Net revenues from collaborations    
Revenues:    
Total revenues5,8449,02542,30634,970
Royalty revenue    
Revenues:    
Total revenues$ 7,205$ 2,278$ 13,705$ 2,720

ALNY Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 657,800$ 866,394
Marketable debt securities1,372,4511,297,890
Marketable equity securities27,25628,122
Accounts receivable, net220,635237,963
Inventory100,453128,962
Prepaid expenses and other current assets145,452132,916
Total current assets2,524,0472,692,247
Property, plant and equipment, net527,474523,494
Operating lease right-of-use assets208,801215,136
Restricted investments49,38849,390
Other assets92,68666,092
Total assets3,402,3963,546,359
Current liabilities:  
Accounts payable59,74698,094
Accrued expenses598,530545,460
Operating lease liability42,07441,967
Deferred revenue54,63942,105
Liability related to the sale of future royalties33,65040,289
Total current liabilities788,639767,915
Operating lease liability, net of current portion253,416261,339
Deferred revenue, net of current portion194,129193,791
Convertible debt1,018,8431,016,942
Liability related to the sale of future royalties, net of current portion1,298,4461,252,015
Other liabilities257,054212,580
Total liabilities3,810,5273,704,582
Commitments and contingencies (Note 13)
Stockholders’ deficit:  
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 202200
Common stock, $0.01 par value per share, 250,000 shares authorized; 124,901 shares issued and outstanding as of June 30, 2023; 123,925 shares issued and outstanding as of December 31, 20221,2501,240
Additional paid-in capital6,647,1736,454,540
Accumulated other comprehensive loss(37,080)(44,654)
Accumulated deficit(7,019,474)(6,569,349)
Total stockholders’ deficit(408,131)(158,223)
Total liabilities and stockholders’ deficit$ 3,402,396$ 3,546,359
Yvonne L. Greenstreet
1660
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.